Koers Evogene Ltd TEL AVIV STOCK EXCHANGE
Aandelen
IL0011050551
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 17 mln. 6,31 mld. 15,81 mln. | Omzet 2025 * | 31,5 mln. 11,69 mld. 29,3 mln. | Marktkapitalisatie | 36,42 mln. 13,52 mld. 33,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -7,42 mld. -18,61 mln. | Nettowinst (verlies) 2025 * | -17 mln. -6,31 mld. -15,81 mln. | EV/omzet 2024 * | 2,14 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,16 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,34% |
Recentste transcriptie over Evogene Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-01-02 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 01-04-22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 01-01-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 17-11-21 |
Sarit Firon
CHM | Chairman | 58 | 11-08-16 |
Leon Recanati
BRD | Director/Board Member | 76 | 01-05-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+22,56% | 46,4 mld. | |
-1,51% | 41,75 mld. | |
+48,83% | 41,37 mld. | |
-3,42% | 29,71 mld. | |
+10,13% | 26,01 mld. | |
-20,44% | 19,52 mld. | |
+26,45% | 12,43 mld. | |
-0,14% | 12,18 mld. | |
-0,47% | 12,13 mld. |